Latest News

Sign up to receive our news releases

More SomaLogic News

New study shows consistency in proteogenomic signals between proteomic measurement platforms

Researchers at the University of Cambridge report the largest, systematic assessment of two different affinity-based proteomic platform technologies to date. By truncating the 5000-plex aptamer-based SomaScan® Assay results down to consider approximately 900 overlapping targets on a polyclonal antibody-based assay and running both assays on the same 485 genotyped samples, the researchers successfully replicated most proteogenomic signals on both platforms.

read more

Events Archive

Global NASH Congress | Webinar

Our presentation at the virtual 2021 Global Nash Congress features Dr. Stephen Williams , who discusses SomaLogics development of serum proteomic tests for liver biopsy components and diagnosis of at-risk NASH. Watch now to learn how these tests can help streamline clinical trials.

watch here

The Somascan® Assay: Biomarker Discovery to Delivery | Virtual Event

As part of the Molecular Medicine Tri-Con virtual conference on February 16, 2021, Dr. Sheri Wilcox of SomaLogic described how the SomaScan Assay has been used to identify protein patterns as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants.

watch here

Building a genetic atlas of the human plasma proteome | WEBINAR

Protein-genotype associations (pQTLs) are an important tool for identifying proteins that link genetic variants with disease states. On August 6, 2020, Dr. Benjamin Sun discussed how he and his colleagues at the University of Cambridge used the SomaScan® Assay to develop a pQTL atlas for the human plasma proteome.

watch here

What Can Proteomics Teach Us About Infectious Disease | WEBINAR

On June 25, 2020, Dr. Kevin Coombs of the University of Manitoba described his work using the SomaScan Assay to identify biological processes associated with infection by Zika virus and various strains of influenza. He also discussed how the SomaScan Assay® could be used to further study infectious disease, including the current COVID-19 pandemic, in the immediate future.

watch here

SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform

SomaLogic and CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction CM Life Sciences II will be renamed and its common stock will be listed on the Nasdaq Global Market under ticker symbol “SLGC.”

read more

SomaLogic Announces Customizable Protein Panels

SomaLogic, Inc., a global leader in proteomics technology, announced today its intention to broaden its proteomics offerings to pharma, biotechnology and academic research customers by adding smaller protein measurement panel products to its market-leading, large-plex offering.

read more

For older news and press releases, please visit our archive.